

**Original article:**

**ALTERATION OF PLASMA BIOCHEMICAL, HAEMATOLOGICAL  
AND OCULAR OXIDATIVE INDICES OF ALLOXAN INDUCED  
DIABETIC RATS BY AQUEOUS EXTRACT OF  
*TRIDAX PROCUMBENS* LINN (ASTERACEAE)**

Jude Chigozie Ikewuchi

Department of Biochemistry, Faculty of Science, University of Port Harcourt, P.M.B. 5323,  
Port Harcourt, Nigeria

E-mail: [ecoli240733@yahoo.com](mailto:ecoli240733@yahoo.com)

**ABSTRACT**

In this study, the effects of an aqueous extract of the leaves of *Tridax procumbens* on the haematology, plasma biochemistry and ocular indices of oxidative stress was investigated in alloxan induced diabetic rats. Diabetes mellitus was induced by injection of alloxan (80 mg/kg body weight), via the tail vein. The extract was administered orally at 100, 200 and 300 mg/kg (both to normal and diabetic rats), and metformin at 50 mg/kg. On gas chromatographic analysis of the alkaloid fraction of the aqueous extract, thirty nine known alkaloids were detected, consisting mainly of 73.91 % akuamidine, 22.33 % voacangine, 1.27 % echitamine, 0.55 % echitamidine, 0.36 % lupanine, 0.27 % crinamidine, 0.23 % augustamine and 0.10 % 6-hydroxypowelline. Tannic acid and  $\beta$ -sitosterol were detected in high quantities. Compared to Test control, the treatment dose-dependently, significantly lowered ( $P<0.05$ ) plasma glucose, triglyceride, very low density lipoprotein cholesterol, total bilirubin, urea, blood urea nitrogen; plasma alkaline phosphatase, alanine and aspartate transaminases, and ocular superoxide dismutase activities, and lymphocyte count. It also significantly increased ( $P<0.05$ ) plasma calcium and ocular ascorbic acid contents, haemoglobin concentration and neutrophil count. This study showed that the extract was hypoglycemic, positively affected the haemopoietic system and integrity and function (dose dependently) of the liver and kidney of the diabetic rats; improved the lipid profile and had no deleterious effect on red cell morphology and protected against oxidative stress in ocular tissues. This study also revealed the presence of pharmacologically active compounds in the leaf extract. All of these, highlight the cardioprotective potential of the leaves of *Tridax procumbens*, and support its use in traditional health care practices for the management of diabetes mellitus.

**Keywords:**  $\beta$ -sitosterol, hypoglycemia, lipid profile, ocular oxidative stress, tannic acid, *Tridax procumbens* Linn

**INTRODUCTION**

Diabetes mellitus is a group of metabolic diseases characterized by elevated glucose in the plasma resulting from defects in insulin secretion, insulin action, or both (American Diabetes Association, 2004; Centers for Disease Control and Prevention, 2008; Wardlaw, 1999). In Nigeria and other

African populations, the past two decades has witnessed the emergence of type 2 diabetes mellitus as a major health problem, affecting about 2-7 % of these populations (Rolfe et al., 1992; Amos et al., 1997). The WHO 2004 report estimated that 1.7 million people in Nigeria had diabetes, with the projection that the number will triple by 2030 (World Health Organization, 2004).

Presently, there is renewed interest in the use of herbal products. This may be attributable to the down turn in the economy, as herbal medicine is perceived to be a cheaper means of treatment (Kamboj, 2000; Acuff et al., 2007). Herbal products can improve glucose metabolism and the overall condition of individuals with diabetes, not only by hypoglycemic effects but also by improving lipid metabolism, antioxidant status, and capillary function (Bailey and Day, 1989). *Tridax procumbens* is one of a number of medicinal herbs that is used in traditional health care practices for the management of diabetes mellitus.

*Tridax procumbens* Linn (Family Asteraceae) is native to Central America and tropical South America, but has spread throughout the tropical and subtropical parts of the world. Its common names are coat buttons, tridax daisy, tridax (United States Department of Agriculture, Agricultural Research Service, 2011). The Ibo people of South Eastern Nigeria call it “mbuli”. It has daisy-like yellow centered white or yellow flowers with three toothed ray floret. The leaves are short, hairy and arrow shaped (Jahangir, 2001). It produces a hard achene fruit that is covered with stiff hairs (Fosberg and Sachet, 1980). It is used as an ornamental or fodder plant, and its leaves are cooked as vegetables (Acharya and Srivastava, 2010; Prajapati et al., 2008). Traditionally, it is used for the treatment of bronchial catarrh, malaria, stomach ache, diarrhoea, epilepsy, diabetes, high blood pressure, haemorrhage, liver problems, and as a hair tonic (Agrawal et al., 2010; Ahirwar et al., 2010; Hemalatha, 2008; Jahangir, 2001; Ravikumar et al., 2005). It possesses anti-septic, insecticidal, parasiticidal properties and has marked depressant action on respiration (Edeoga et al., 2005; Salahdeen et al., 2004; Saxena and Albert, 2005).

Ikewuchi et al. (2009) and Ikewuchi and Ikewuchi (2009a, b) reported the nutrient/nutraceutical potential of the leaves. The protective effects of aqueous extract of the leaves against cholesterol and salt loading in Wistar albino rats (Ikewuchi and Ikewuchi, 2009c; Ikewuchi et al., 2010), as

well as its weight reducing (Ikewuchi et al., 2011a) and hypotensive (Ikewuchi et al., 2011b) activities have also been reported. Prabhu et al. (2011) reported the analgesic activity of the leaves. In this study, the effects of an aqueous extract of the leaves of *Tridax procumbens* Linn on haematology, plasma biochemistry and ocular indices of oxidative stress in normal and alloxan-induced diabetic Wistar rats were investigated.

## MATERIALS AND METHODS

### *Preparation of plant extract*

Samples of the fresh *Tridax procumbens* plants (Figure 1) were collected from within the Choba and Abuja Campuses of University of Port Harcourt, Nigeria. After due identification at the University of Port Harcourt Herbarium, Port Harcourt, Nigeria, the identity was confirmed/authenticated by Dr. Michael C. Dike of the Taxonomy Unit, Department of Forestry and Environmental Management, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria; and Mr. John Ibe, the Herbarium Manager of the Forestry Department, National Root Crops Research Institute (NRCRI), Umuahia, Nigeria. The samples were rid of dirt and the leaves removed, oven dried at 55°C and ground into powder. The resultant powder was soaked in hot, boiled distilled water for 12 h, after which the resultant mixture was filtered and the filtrate, hereinafter referred to as the aqueous extract was stored in a refrigerator for subsequent use. A known volume of this extract was evaporated to dryness, and the weight of the residue used to determine the concentration of the filtrate, which was in turn used to determine the dose of administration of the extract. The resultant residue was used for the phytochemical study.

### ***Determination of the phytochemical content of the crude aqueous leaf extract***

#### ***Calibration, identification and quantification***

Standard solutions were prepared in methanol for alkaloids and tannins, and methylene chloride for phytosterols. The linearity of the dependence of response on concentration was verified by regression analysis. Identification was based on comparison of retention times and spectral data with standards. Quantification was performed by establishing calibration curves for each compound determined, using the standards.

#### ***Determination of alkaloid composition***

The extraction was carried out according to the method of Tram et al. (2002). The alkaloid fraction of the crude aqueous extract was extracted with methanol and subjected to gas chromatographic analysis. Chromatographic analyses were carried out on an HP 6890 (Hewlett Packard, Wilmington, DE, USA), GC apparatus, fitted with a flame ionization detector (FID), and powered with HP Chemstation Rev. A 09.01 (1206) software, to quantify and identify compounds. The column was a capillary DB-5MS (30 m × 0.25 mm × 0.25 µm film thickness). The inlet and detection temperatures were 250 and 320 °C. Split injection was adopted with a split ratio of 20:1. Nitrogen was used as the carrier gas. The hydrogen and compressed air pressures were 28 psi and 38 psi. The oven was programmed as follows: initial temperature at 60 °C for 5 min. First ramping at 10 °C/min for 20 min was followed by a second ramping at 15 °C/min for 4 min.

#### ***Determination of phytosterol composition***

Extraction of oil was carried out according to AOAC method 999.02 (AOAC International, 2002), while the analysis of sterols was carried out according to AOAC method 994.10 (AOAC International, 2000). This involved extraction of the lipid fraction from homogenized sample material, followed by alkaline hydrolysis (saponifica-

tion), extraction of the non-saponifiables, clean-up of the extract, derivatisation of the sterols, and separation and quantification of the sterol derivatives by gas chromatography (GC) using a capillary column. Chromatographic analyses were carried out on an HP 6890 (Hewlett Packard, Wilmington, DE, USA), GC apparatus, fitted with a flame ionization detector (FID), and powered with HP Chemstation Rev. A 09.01 (1206) software, to quantify and identify compounds. The column was HP INNOWax Column (30 m × 0.25 mm × 0.25 µm film thickness). The inlet and detection temperatures were 250 and 320 °C. Split injection was adopted with a split ratio of 20:1. Nitrogen was used as the carrier gas. The hydrogen and compressed air pressures were 22 psi and 35 psi. The oven was programmed as follows: initial temperature at 60 °C, first ramping at 10 °C/min for 20 min, maintained for 4 min, followed by a second ramping at 15 °C/min for 4 min, maintained for 10 min.

#### ***Determination of tannin composition***

Extraction was carried out according to the method of Luthar (1992). The tannin fraction of the crude aqueous extract above was extracted with methanol and subjected to gas chromatographic analysis. Chromatographic analyses were carried out on an HP 6890 (Hewlett Packard, Wilmington, DE, USA), GC apparatus, fitted with a flame ionization detector (FID), and powered with HP Chemstation Rev. A 09.01 (1206) software, to quantify and identify compounds. The column was HP 5 Column (30 m × 0.25 mm × 0.25 µm film thickness). The inlet and detection temperatures were 250 and 320 °C. Split injection was adopted with a split ratio of 20:1. Nitrogen was used as the carrier gas. The hydrogen and compressed air pressures were 28 psi and 40 psi. The oven was programmed as follows: initial temperature at 120 °C, followed by ramping at 10 °C/min for 20 min.

### Experimental design for the anti-diabetic study

Male Wistar albino rats (weighing 180-200 g at the start of the study) were collected from the animal house of the Department of Physiology, University of Nigeria, Enugu Campus. All the experiments were conducted in accordance with the internationally accepted principles for laboratory animal use and care as found in the European Community Guidelines (EEC Directive of 1986; 86/609/EEC). The rats were weighed and sorted into nine groups (Table 1) of five animals each, so that their average weights were approximately equal. The animals were housed in plastic cages. After a one-week acclimatization period on guinea growers mash (Port Harcourt Flour Mills, Port Harcourt, Nigeria), the animals were fasted overnight, and their baseline fasting blood glucose level (FBS) determined using multiCarein™ triglyceride strips and glucometer (Biochemical Systems International, Arezzo, Italy), by collecting blood via tail cut. Diabetes was induced by injection of a freshly prepared solution of alloxan (80 mg/kg body weight) in normal saline, via the tail vein of five groups, while the other four groups were injected with normal saline alone. The dosage of administration of alloxan was adapted from Radwan (2001). Three days after administration of the alloxan, the animals were again fasted and blood collected via tail cutting blood (Burcelin et al., 1995), for the determination of their fasting glucose levels. It was found that the rats had moderate diabetes, having hyperglycemia (that is, with blood glucose of over 150 % of the control). Then the rats were kept for 3 days to stabilize the diabetic condition (Jyoti et al., 2002) before commencing the treatment, which lasted for ten days. The Diabetmin™ (metformin HCl) and extracts were administered daily by intra-gastric gavages. The dosages of administration of the extracts were adopted and modified from Ikewuchi and Ikewuchi (2009c) and Ikewuchi et al. (2010). The animals were allowed food and water *ad libitum*. The fasting glucose levels were taken on days 5 and 10. The animals were al-

lowed normal feed and water *ad libitum*. At the end of the treatment period, they were weighed, fasted overnight and anaesthetized by exposure to chloroform. While under anesthesia, they were sacrificed and blood was collected from each rat into heparin and EDTA sample bottles. Whole blood was immediately used to determine the triglyceride levels (using multiCarein strips). Then the eyes were removed and stored for the determination of the ocular markers of oxidative stress. The heparin anticoagulated blood samples were centrifuged at 1000 g for 10 min, after which their plasma was collected and stored for subsequent analysis, while the EDTA anticoagulated blood samples were used for the haematological analysis.

**Table 1:** Experimental design for the anti-diabetic screening

S/N	ID	Treatment
1	Normal	Normal saline and water
2	Test control	Alloxan and water
3	Reference treatment (Reference)	Alloxan and metformin (50 mg/Kg body weight)
4	Treatment control I (TPC1)	Normal saline and extract (100 mg/Kg)
5	Treatment control II (TPC2)	Normal saline and extract (200 mg/Kg)
6	Treatment control III (TPC3)	Normal saline and extract (300 mg/Kg)
7	Treatment I (TP1)	Alloxan and extract (100 mg/Kg)
8	Treatment II (TP2)	Alloxan and extract (200 mg/Kg)
9	Treatment III (TP3)	Alloxan and extract (300 mg/Kg)

### Determination of the plasma biochemical indices

The plasma glucose concentration was determined using the multiCarein™ glucose strips and glucometer (Biochemical Systems International, Arezzo, Italy). Plasma triglyceride concentration was determined using multiCarein™ triglyceride strips and glucometer (Biochemical Systems International, Arezzo, Italy). Plasma total and high density lipoprotein cholesterol concentrations were assayed enzymatically with Randox commercial test kits

(Randox Laboratories, Crumlin, England, UK). Plasma VLDL- and LDL-cholesterol concentrations were calculated using the Friedewald equation (Friedewald, 1972) as follows:

$$[\text{LDL cholesterol}] \left( \frac{\text{mmol}}{\text{L}} \right) = [\text{Total cholesterol}] - [\text{HDL cholesterol}] - \frac{(\text{Triglyceride})}{2.2} \quad (\text{Eqn 1})$$

$$[\text{VLDL cholesterol}] \left( \frac{\text{mmol}}{\text{L}} \right) = \frac{(\text{Triglyceride})}{2.2} \quad (\text{Eqn 2})$$

Plasma non-HDL cholesterol concentration was determined as reported by Brunzell *et al.* (2008):

$$[\text{Non-HDL cholesterol}] = [\text{Total cholesterol}] - [\text{HDL cholesterol}] \quad (\text{Eqn 3})$$

The atherogenic indices were calculated as earlier reported by Ikewuchi and Ikewuchi (2009c, d, 2010) using the following formulae:

$$\text{Cardiac Risk Ratio (CRR)} = \frac{(\text{Total cholesterol})}{(\text{HDL cholesterol})} \quad (\text{Eqn 4})$$

$$\text{Atherogenic Coefficient (AC)} = \frac{[\text{Total cholesterol}] - (\text{HDL cholesterol})}{(\text{HDL cholesterol})} \quad (\text{Eqn 5})$$

$$\text{Atherogenic Index of Plasma (AIP)} = \frac{\log(\text{Triglyceride})}{(\text{HDL cholesterol})} \quad (\text{Eqn 6})$$

The plasma activities of alanine transaminase, aspartate transaminase, and alkaline phosphatase, were determined using Randox test kits (Randox Laboratories, Crumlin, England, UK). The activities of alanine and aspartate transaminases were respectively measured by monitoring at 546 nm the concentrations of pyruvate and oxaloacetate hydrazones formed with 2,4-dinitrophenylhydrazine. The activity of alkaline phosphatase was determined by monitoring the degradation of p-nitrophenylphosphate to p-nitrophenol, at 405 nm. Plasma total and conjugated bilirubin, urea and total protein concentrations were determined using Randox test kits (Randox

Laboratories, Crumlin, England, UK). The wavelength for the determination of conjugated bilirubin and urea was 546 nm and that of total bilirubin was 578 nm. Plasma total protein was determined by the Biuret method using Randox test kits, and the concentration of the resultant coloured complex was measured at 560 nm. Plasma sodium and potassium concentration was determined by flame photometry, according to AOAC Official Method 956.01 (AOAC International, 2006). Plasma calcium concentration was determined by the cresol phthalain complexone method (Baginsky *et al.*, 1973), and the concentration of the resultant complex was measured at 575 nm. Plasma chloride and bicarbonate concentrations were determined by titrimetric methods (Cheesbrough, 2006).

#### **Determination of the haematological indices**

Haematological indices were determined using Medonic M<sup>16</sup> Haematological Analyser (Nelson Biomedical Limited., UK).

#### **Determination of ocular indices of oxidative stress**

Each eye was homogenized in 4 mL of 0.001 mol/L phosphate buffer (pH 7.4). The resultant homogenate was centrifuged at 1000 x g for 15 min, and the supernatants were collected and stored in the refrigerator for the assays. The protein contents of the homogenates were determined by the biuret method, using Randox test kits (Randox Laboratories, Crumlin, England, UK).

The method adopted for the analysis of malondialdehyde was that of Hunter *et al.* (1963) as modified by Gutteridge and Wilkins (1982). The concentration of the resultant malondialdehyde - thiobarbituric acid complex (or adduct) was measured at 532 nm. Ascorbic acid content was estimated by iodine titration as reported by Ikewuchi and Ikewuchi (2011). Catalase activity was determined according to the method of Beers and Sizer (1952). The concentration of the residual hydrogen peroxide was measured at 420 nm. Superoxide dismutase

activity was determined according to the method of Misra and Fridovich (1989). The degree of inhibition of the auto-oxidation of adrenaline (which reflects the activity of superoxide dismutase) was determined by measuring the concentration of the resultant adrenochrome, at 520 nm. The amount of enzyme that produced 50 % inhibition was defined as one unit of the enzyme activity.

### Statistical analysis of data

All values are reported as the mean  $\pm$  standard error in the mean (s.e.m.). The values of the variables were analyzed for statistically significant differences using the Student's *t*-test, with the help of SPSS Statistics 17.0 package (SPSS Inc., Chicago III).  $P < 0.05$  was assumed to be significant. Graphs were drawn using Microsoft Office Excel, 2010 software.

## RESULTS

Table 2 shows the alkaloid composition of an aqueous extract of the leaves of *T. procumbens*. Thirty nine known alkaloids were detected, consisting mainly of 73.91 % akuamidine, 22.33 % voacangine, 1.27 % echitamine, 0.55 % echitamidine, 0.36 % lupanine, 0.27 % crinamidine, 0.23 % augustamine and 0.10 % 6-hydroxypowelline.

**Table 2:** The composition of the alkaloid fraction of an aqueous extract of the leaves of *Tridax procumbens*

Compounds	Retention time (min)	Composition (mg/kg)
Choline	7.096	0.007442
Trigonelline	7.641	Not detected
Angustifoline	8.109	Not detected
Sparteine	8.952	0.002921
Ellipicine	9.680	0.006273
Lupanine	11.041	0.105692
13- $\alpha$ -Hydrorhombifoline	11.286	0.006579
9-Octadecenamide	12.936	0.006590
Dihydro-oxo-demethoxyhaemanthamine	14.150	0.011062
Augustamine	14.918	0.068184
Oxoassoanine	15.395	0.009922

Compounds	Retention time (min)	Composition (mg/kg)
Cinchonidine	16.246	0.018697
Cinchonine	16.369	0.011521
Crinane-3 $\alpha$ -ol	16.491	0.025934
Buphanidrine	16.669	0.011993
Indicine-N-oxide	17.547	0.010321
Powelline	18.590	0.013073
Undulatine	18.840	0.009488
Ambelline	19.678	0.005772
6-Hydroxy-buphanidrine	20.473	0.021053
Acronycine	21.130	0.019698
Monocrotaline	21.328	0.021175
6-Hydroxypowelline	21.821	0.029815
Nitidine	22.366	0.013351
Crinamidine	23.968	0.079650
1 $\beta$ ,2 $\beta$ -Epoxy-ambelline	24.616	0.021799
6-Hydroxy-undulatine	24.791	0.016275
Epoxy-3,7-dimethoxy-11-one	25.482	0.002423
Akuamidine	26.837	21.568600
Echitamidine	26.952	0.161556
Voacangine	27.062	6.516560
Mitraphylin	27.649	0.000004
Camptothecin	28.096	0.004965
Echitamine	28.644	0.370808
Colchicine	28.862	0.002308
Emetine	29.578	0.000822
Tetrandrine	29.743	0.000327
Thalicarpin	30.164	0.000024
Paclitaxel	32.338	0.000195
Total		29.182800

Table 3 shows the phytosterol and tannin composition of an aqueous extract of the leaves of *T. procumbens*. The sterol fraction consisted 100 % of sitosterol, with cholesterol, cholestanol, ergosterol, campesterol, stigmasterol and 5-avenasterol not detected. The tannin fraction consisted 100 % of tannic acid.

**Table 3:** Composition of the phytosterol and tannin fractions of an aqueous extract of the leaves of *Tridax procumbens*

Compounds	Retention time (min)	Composition (mg/kg)
<b>Phytosterols</b>		
Sitosterol	24.790	115.79
<b>Tannins</b>		
Tannic acid	19.201	5294.78



Table 4 shows the time course of the effect of an aqueous extract of the leaves of *T. procumbens* on the plasma glucose levels of normal and alloxan treated rats. On day 0, the plasma fasting glucose concentration of the alloxan treated animals were significantly higher ( $P<0.05$ ) than the untreated animals (Normal, Treatment control 1, Treatment control 2 and Treatment control 3). On days 5 and 10, the plasma fasting glucose levels of the animals administered the extracts were significantly lower ( $P<0.05$ ) than corresponding Test controls and values on day 0. The percentage reductions in plasma fasting glucose levels of the treated rats on days 5 and 10, were significantly higher ( $P<0.05$ ) than the corresponding values of the Test control group.

Tables 5 and 6 show the effect of an aqueous extract of the leaves of *T. procumbens* on the plasma lipid profiles and atherogenic indices of normal and alloxan treated rats. The 300 mg/kg treatment produced a significantly lower ( $P<0.05$ ) plasma triglyceride and VLDL cholesterol levels, compared to Test control. There were no significant differences in the total-, HDL-, LDL- and non-HDL cholesterol levels, as well as the atherogenic indices of the test groups and Test control. The cardiac risk ratio and atherogenic coefficient of Treatment 1 and the atherogenic index of plasma of Treatment 3 were lower though not significantly than the Test control.

**Table 4:** Effect of an aqueous extract of the leaves of *Tridax procumbens* on the plasma glucose profiles of normal and alloxan-induced diabetic rats

Treatment group	Magnitude				
	Day 0 (mg/dL)	Day 5		Day 10	
		Value (mg/dL)	% Reduction	Value (mg/dL)	% Reduction
Normal	96.00±3.11 <sup>a</sup>	98.35±4.63 <sup>a</sup>	-3.55±8.68 <sup>a,d</sup>	104.20±2.27 <sup>a,b,d</sup>	-9.11±4.95 <sup>a</sup>
Test control	155.40±48.67 <sup>c</sup>	208.00±16.07 <sup>c,*</sup>	-65.45±29.31 <sup>c</sup>	179.50±29.11 <sup>c,*</sup>	-50.27±33.96 <sup>c</sup>
Reference treatment	105.90±0.87 <sup>d</sup>	89.33±0.94 <sup>a,d,*</sup>	15.65±0.25 <sup>d,e</sup>	110.00±9.61 <sup>d,*</sup>	-3.95±9.52 <sup>a</sup>
Treatment control 1	91.75±2.97 <sup>a</sup>	83.00±3.92 <sup>d,*</sup>	9.69±1.58 <sup>a,f</sup>	106.00±1.76 <sup>d,e,*</sup>	-13.13±5.32 <sup>a,c</sup>
Treatment control 2	85.75±2.29 <sup>a</sup>	51.25±4.04 <sup>e,*</sup>	39.71±6.12 <sup>b,g</sup>	108.00±3.56 <sup>a,d,*</sup>	-26.66±7.34 <sup>a,c</sup>
Treatment control 3	82.50±1.72 <sup>e</sup>	66.67±2.11 <sup>f,*</sup>	18.91±3.98 <sup>b,e,f</sup>	100.00±3.13 <sup>b,e,*</sup>	-21.66±6.03 <sup>c</sup>
Treatment 1	146.33±4.13 <sup>c</sup>	111.00±2.53 <sup>g,*</sup>	24.06±1.33 <sup>b</sup>	128.33±2.54 <sup>f,*</sup>	12.12±2.29 <sup>b</sup>
Treatment 2	138.67±1.97 <sup>f</sup>	91.00±2.24 <sup>a,d,*</sup>	34.31±2.01 <sup>g</sup>	122.00±3.85 <sup>a,g,*</sup>	12.05±2.19 <sup>b</sup>
Treatment 3	233.33±4.32 <sup>b</sup>	151.00±3.03 <sup>b,*</sup>	35.19±1.76 <sup>g</sup>	134.00±5.79 <sup>f,g,*</sup>	42.31±3.57 <sup>d</sup>

Values are mean ± s.e.m., n=5, per group.

<sup>a,b,c</sup>Values in the same column with different superscripts are significantly different at  $P<0.05$ .

\* $P<0.05$  compared to corresponding values on day 0.

% reduction = percentage reduction from the corresponding values on day 0.

**Table 5:** Effect of an aqueous extract of the leaves of *Tridax procumbens* on the plasma lipid profile of normal and alloxan-induced diabetic rats

Treatment group	Concentration (mmol/L)					
	Triglyceride	Total cholesterol	HDL cholesterol	VLDL cholesterol	LDL cholesterol	Non-HDL cholesterol
	Normal	0.80±0.04 <sup>a</sup>	1.89±0.05 <sup>a,b,d</sup>	1.11±0.02 <sup>c,d</sup>	0.37±0.02 <sup>c</sup>	0.41±0.07 <sup>c,k</sup>
Test control	0.84±0.04 <sup>a,b</sup>	1.74±0.04 <sup>a</sup>	0.73±0.15 <sup>a,c,k</sup>	0.38±0.02 <sup>a,c</sup>	0.63±0.15 <sup>a,c,d,f</sup>	1.01±0.14 <sup>a,c</sup>
Reference treatment	0.88±0.05 <sup>b</sup>	2.24±0.18 <sup>a,b,d</sup>	1.26±0.14 <sup>a,b,c,d</sup>	0.40±0.02 <sup>a</sup>	0.58±0.28 <sup>a,c,d,f</sup>	0.98±0.26 <sup>a,c</sup>
Treatment control 1	0.96±0.05 <sup>a,b</sup>	1.81±0.11 <sup>a,b,d</sup>	1.16±0.07 <sup>d</sup>	0.43±0.02 <sup>a,c</sup>	0.23±0.05 <sup>b,d</sup>	0.67±0.04 <sup>a</sup>
Treatment control 2	0.83±0.04 <sup>a</sup>	1.86±0.27 <sup>a,b,d</sup>	0.91±0.05 <sup>b,k,l</sup>	0.38±0.02 <sup>c,f</sup>	0.57±0.33 <sup>a,b,c,f</sup>	0.95±0.32 <sup>a,b,c</sup>
Treatment control 3	0.97±0.07 <sup>b</sup>	1.78±0.03 <sup>a,b</sup>	1.39±0.10 <sup>d</sup>	0.44±0.03 <sup>a,f</sup>	-0.04±0.11 <sup>b</sup>	0.40±0.09 <sup>b</sup>
Treatment 1	0.82±0.14 <sup>a,b,d</sup>	2.01±0.12 <sup>a,c</sup>	0.83±0.05 <sup>a</sup>	0.37±0.06 <sup>a,b,c</sup>	0.80±0.10 <sup>a,c</sup>	1.18±0.14 <sup>c</sup>
Treatment 2	1.02±0.09 <sup>a,b</sup>	2.03±0.05 <sup>c,d</sup>	1.04±0.12 <sup>a,b,c,d</sup>	0.46±0.04 <sup>a,c</sup>	0.53±0.19 <sup>a,c,d,f</sup>	0.99±0.16 <sup>a,c</sup>
Treatment 3	0.58±0.01 <sup>d</sup>	1.63±0.06 <sup>b</sup>	0.91±0.04 <sup>a,l</sup>	0.27±0.00 <sup>b</sup>	0.45±0.02 <sup>f,k</sup>	0.72±0.02 <sup>a</sup>

Values are mean ± s.e.m., n=5, per group.

<sup>a,b,c</sup>Values in the same column with different superscripts are significantly different at  $P<0.05$ .

**Table 6:** Effect of an aqueous extract of the leaves of *Tridax procumbens* leaves on the atherogenic indices of normal and alloxan-induced diabetic rats

Treatment group	Magnitude		
	Cardiac risk ratio	Atherogenic coefficient	Atherogenic index of plasma
Normal	1.70±0.07 <sup>a,c</sup>	0.70±0.07 <sup>a,c</sup>	-0.14±0.02 <sup>c,f</sup>
Test control	2.74±0.44 <sup>a,c</sup>	1.74±0.44 <sup>a,c</sup>	0.09±0.06 <sup>a</sup>
Reference treatment	1.89±0.32 <sup>a,b,c</sup>	0.89±0.32 <sup>a,b,c</sup>	-0.15±0.05 <sup>d,f,h</sup>
Treatment control 1	1.59±0.03 <sup>a</sup>	0.59±0.03 <sup>a</sup>	-0.08±0.04 <sup>b,c,d</sup>
Treatment control 2	2.15±0.49 <sup>a,b,c</sup>	1.15±0.49 <sup>a,b,c</sup>	-0.04±0.03 <sup>a,b,h</sup>
Treatment control 3	1.31±0.09 <sup>b</sup>	0.31±0.09 <sup>b</sup>	-0.16±0.02 <sup>d,f</sup>
Treatment 1	1.65±0.54 <sup>a,b,c</sup>	0.65±0.54 <sup>a,b,c</sup>	-0.03±0.07 <sup>a,b,c,d,t</sup>
Treatment 2	2.06±0.26 <sup>a,c</sup>	1.06±0.26 <sup>a,c</sup>	-0.01±0.04 <sup>a,b,c</sup>
Treatment 3	1.79±0.01 <sup>c</sup>	0.79±0.01 <sup>c</sup>	-0.19±0.01 <sup>f</sup>

Values are mean ± s.e.m., n=5, per group.

<sup>a,b,c</sup>Values in the same column with different superscripts are significantly different at  $P<0.05$ .

Tables 7 and 8 show the effect of an aqueous extract of the leaves of *T. procumbens* on the plasma biochemistry of normal and alloxan treated rats. The alkaline phosphatase activity of the animals on Treatment 2 was significantly lower ( $P<0.05$ ) than Test control, while that of Treatment 3 was significantly higher ( $P<0.05$ ). The plasma alanine transaminase activity, urea, blood urea nitrogen and total bilirubin levels of Treatment 1 and Treatment 2 were significantly lower ( $P<0.05$ ) than Test control, while that of Treatment 3 was higher, though not significantly. The aspartate transaminase activity of Treatment 2 and Treatment 3 were significantly lower

( $P<0.05$ ) than Test control, while that of Treatment 1 was not. The plasma calcium level of the animals on Treatment 1 was significantly higher ( $P<0.05$ ) than Test control; those of Treatment 2 and Treatment 3 were not significantly different. There were no significant differences between the plasma conjugated and unconjugated bilirubin, unconjugated/conjugated bilirubin ratio, total protein, sodium, potassium and chloride levels of the tests and Test control. The plasma bicarbonate level of the animals on Treatment 3 was significantly lower ( $P<0.05$ ) than Test control, while those of Treatment 1 and Treatment 2 were not.

**Table 7:** Effect of an aqueous extract of the leaves of *Tridax procumbens* on the plasma hepatospecific markers of normal and alloxan-induced diabetic rats

Treatment group	Magnitude							
	Alkaline phosphatase activity (U/L)	Alanine transaminase activity (U/L)	Aspartate transaminase activity (U/L)	Total bilirubin level (μmol/L)	Direct bilirubin level (μmol/L)	Unconjugated bilirubin level (μmol/L)	Free/direct bilirubin ratio	Total protein level (mg/dL)
Normal	316.2±15.5 <sup>d</sup>	23.5±2.8 <sup>a,c</sup>	25.9±0.9 <sup>a,f</sup>	2.9±0.1 <sup>a,d</sup>	2.3±0.1 <sup>a,c</sup>	0.7±0.1 <sup>a</sup>	0.3±0.0 <sup>a,c</sup>	51±0.8 <sup>a</sup>
Test control	567.9±121.6 <sup>d</sup>	25.6±0.3 <sup>a</sup>	27.4±0.7 <sup>a,d,f</sup>	3.5±0.2 <sup>c,f</sup>	2.7±0.2 <sup>c</sup>	0.8±0.0 <sup>a,b,d</sup>	0.3±0.0 <sup>a,c</sup>	60±2.2 <sup>b,c</sup>
Reference treatment	176.6±1.2 <sup>d</sup>	21±0.3 <sup>c</sup>	27.1±3.1 <sup>a,d,f</sup>	3.6±0.1 <sup>c,f</sup>	2.2±0.1 <sup>a,c</sup>	1.4±0.2 <sup>d</sup>	0.7±0.1 <sup>b</sup>	57.6±2.8 <sup>a,b</sup>
Treatment control 1	334.0±85.2 <sup>a,d</sup>	30.5±1.8 <sup>a,d</sup>	23.2±1.3 <sup>a,b,f</sup>	2.5±0.1 <sup>b</sup>	1.6±0.2 <sup>f</sup>	0.8±0.2 <sup>a,c</sup>	0.6±0.2 <sup>a,b,c</sup>	54.7±1.6 <sup>a,b</sup>
Treatment control 2	411.9±73.9 <sup>a,d</sup>	34.9±2.1 <sup>a</sup>	24.9±2.3 <sup>a,b,f</sup>	2.0±0.2 <sup>h</sup>	1.3±0.1 <sup>b</sup>	0.7±0.2 <sup>a,b</sup>	0.6±0.2 <sup>a,b,c</sup>	57.8±3.2 <sup>a,b</sup>
Treatment control 3	413.1±109.6 <sup>a,b,d</sup>	28.5±3.3 <sup>a,c</sup>	22.2±1.2 <sup>a,b,c,i</sup>	2.5±0.2 <sup>a,b</sup>	2.0±0.2 <sup>a,f</sup>	0.6±0.2 <sup>a,b</sup>	0.3±0.2 <sup>a,b,c</sup>	57.0±0.8 <sup>b</sup>
Treatment 1	575.5±134.9 <sup>a,b,d</sup>	23.36±2.2 <sup>c,d</sup>	23.8±1.6 <sup>f,h</sup>	3.0±0.1 <sup>a,d</sup>	2.1±0.3 <sup>a,b,c,f</sup>	1.0±0.2 <sup>a,b,d</sup>	0.6±0.2 <sup>a,b,c</sup>	64.9±1.1 <sup>c</sup>
Treatment 2	391.9±93.4 <sup>a</sup>	22.2±1.1 <sup>c</sup>	17.0±2.3 <sup>h,j</sup>	3.1±0.2 <sup>d,f</sup>	2.4±0.1 <sup>a,c</sup>	0.7±0.1 <sup>a,b</sup>	0.3±0.1 <sup>c</sup>	52.2±2.5 <sup>a,b</sup>
Treatment 3	941.2±107.4 <sup>b</sup>	31.7±1.3 <sup>a,d</sup>	17.7±1.1 <sup>c,i</sup>	3.6±0.0 <sup>c</sup>	2.5±0.2 <sup>a,c</sup>	1.2±0.1 <sup>b,c,d</sup>	0.5±0.1 <sup>a,b</sup>	56.2±1.2 <sup>b</sup>

Values are mean ± s.e.m., n=5, per group.

<sup>a,b,c</sup>Values in the same column with different superscripts are significantly different at  $P<0.05$ .



**Table 8:** Effect of an aqueous extract of the leaves of *Tridax procumbens* on the plasma electrolyte profiles of normal and alloxan-induced diabetic rats

Treatment group	Concentration						
	Urea (mmol/L)	Blood Urea Nitrogen (BUN, mg/dL)	Calcium (mmol/L)	Sodium (mg/dL)	Potassium (mg/dL)	Chloride (meq/L)	Bicarbonate (meq/L)
Normal	20.9±2.2 <sup>a,c</sup>	58.7±6.1 <sup>a</sup>	2.1±0.1 <sup>a,d</sup>	129.2±0.8 <sup>a,b</sup>	5.2±0.2 <sup>a</sup>	98.8±1.5 <sup>a,b</sup>	18.2±0.6 <sup>a,b,c</sup>
Test control	43.7±1.3 <sup>i</sup>	122.8±3.8 <sup>d</sup>	1.9±0.1 <sup>b,k</sup>	130.0±0.7 <sup>a,b</sup>	5.1±0.1 <sup>a,b</sup>	98.5±0.7 <sup>a</sup>	19.5±0.5 <sup>a</sup>
Reference treatment	12.7±2.3 <sup>d</sup>	35.6±6.4 <sup>c</sup>	2.0±0.1 <sup>b,d,f</sup>	148.7±12.4 <sup>a,b</sup>	9.2±1.9 <sup>a,b</sup>	114.7±10.1 <sup>a,b</sup>	18.0±0.5 <sup>c</sup>
Treatment control 1	14.7±0.7 <sup>d</sup>	41.4±2.0 <sup>c</sup>	2.1±0.1 <sup>a,d</sup>	142.0±8.5 <sup>a,b</sup>	5.2±0.4 <sup>a,b</sup>	146.5±37.3 <sup>a,b</sup>	18.0±2.2 <sup>a,b,c</sup>
Treatment control 2	15.7±0.9 <sup>a,b,d</sup>	44.0±2.6 <sup>a,c</sup>	2.1±0.0 <sup>a,d</sup>	130.8±1.2 <sup>a,b</sup>	5.0±0.2 <sup>a,b</sup>	102.8±1.4 <sup>a,b</sup>	15.3±1.6 <sup>b,c</sup>
Treatment control 3	17.1±1.0 <sup>b,h</sup>	48.0±2.9 <sup>d,f</sup>	1.9±0.1 <sup>b,f</sup>	128.0±1.8 <sup>a,b</sup>	5.7±0.5 <sup>a,b</sup>	97.3±1.6 <sup>a,b</sup>	14.3±1.0 <sup>b</sup>
Treatment 1	26.6±3.9 <sup>a,c,h</sup>	74.7±11.1 <sup>a,f</sup>	2.2±0.0 <sup>a</sup>	133.5±1.1 <sup>a</sup>	5.3±0.2 <sup>a,b</sup>	97.7±1.3 <sup>a,b</sup>	17.3±0.7 <sup>a,c,d</sup>
Treatment 2	23.8±1.8 <sup>c,n</sup>	66.7±4.9 <sup>a</sup>	2.1±0.1 <sup>a,b,d,t</sup>	131.3±1.0 <sup>a,b</sup>	4.8±0.1 <sup>b</sup>	102.8±1.7 <sup>b</sup>	17.3±0.9 <sup>a,c,t</sup>
Treatment 3	54.2±0.5 <sup>k</sup>	152.1±1.4 <sup>b</sup>	1.9±0.0 <sup>f,k</sup>	128.0±0.7 <sup>b</sup>	5.4±0.1 <sup>a</sup>	97.0±2.8 <sup>a,b</sup>	16.0±0.5 <sup>b,d,f</sup>

Values are mean ± s.e.m., n=5, per group.


<sup>a,b,c</sup>Values in the same column with different superscripts are significantly different at  $P<0.05$ .

Table 9 shows the effect of an aqueous extract of the leaves of *T. procumbens* on ocular markers of oxidative stress of normal and alloxan treated rats. The ocular ascorbic acid contents of the test animals were higher than the Test control; with Treatment 2 being significantly so ( $P<0.05$ ). There were no significant differences in the ocular malondialdehyde levels of all the groups. The ocular catalase activities of the test animals were lower though not significantly than the Test control. The ocular superoxide dismutase activities of the test animals were lower than the Test control; with Treatment 3 being significantly so ( $P<0.05$ ).

Table 10 shows the effect of an aqueous extract of the leaves of *T. procumbens* on the haematological indices of normal and alloxan treated rats. The haematocrit, red cell and monocyte counts of Treatment 2 and Treatment 3 were higher though not significantly, than Test control, while that of Treatment 1 was lower. The haemoglobin concentrations of Treatment 2 and Treatment 3 were significantly higher ( $P<0.05$ ) than Test control, while that of Treatment 1 was lower. There were no significant differences in the total white cell

counts, mean cell volume, mean cell haemoglobin and mean cell haemoglobin concentrations of the test groups and Test control. The neutrophil count of Treatment 2 was significantly higher ( $P<0.05$ ) than Test control, while those of Treatment 1 and Treatment 3 were not. The lymphocyte count of Treatment 2 was significantly lower ( $P<0.05$ ) than Test control, while those of Treatment 1 and Treatment 3 were not. The platelet counts of the test groups were higher (though not significantly) than the Test control. Figure 1 shows the frequency distribution of the effect of an aqueous extract of the leaves of *T. procumbens* on the cell morphology of normal and alloxan treated rats. All the cells from the animals on Treatment 2 and Treatment 3 were normochromic and normocytic, while those from Treatment 1 were 66 % hypochromic and 33 % normochromic; and 25 % poikilocytic, 50 % normocytic and 25 % anisocytic. This result shows that the extract had no deleterious effect on red cell morphology.

**Figure 1:** Frequency distribution of the effect of an aqueous extract of the leaves of *Tridax procumbens* on red cell morphology of normal and alloxan-induced diabetic rats. TPC1 = Treatment control 1, TPC2 = Treatment control 2, TPC3 = Treatment control 3, TP1 = Treatment 1, TP2 = Treatment 2, TP3 = Treatment 3.



**Table 9:** Effect of an aqueous extract of the leaves of *Tridax procumbens* on ocular markers of oxidative stress in normal and alloxan-induced diabetic rats

Treatment group	Magnitude			
	Ascorbic acid content ( $\mu\text{mole/g protein}$ )	Malondialdehyde content ( $\mu\text{mol/g protein}$ )	Catalase activity (Units/mg protein)	SOD activity (Units/mg protein)
Normal	11.23 $\pm$ 1.71 <sup>a,b,c,h</sup>	0.09 $\pm$ 0.01 <sup>a,c,d</sup>	20.60 $\pm$ 3.61 <sup>a,c</sup>	0.20 $\pm$ 0.02 <sup>a,c</sup>
Test control	8.72 $\pm$ 0.34 <sup>a,f</sup>	0.09 $\pm$ 0.01 <sup>c,d</sup>	25.84 $\pm$ 3.68 <sup>a,b,c,d</sup>	0.16 $\pm$ 0.02 <sup>c,d,f,k</sup>
Reference treatment	8.30 $\pm$ 0.42 <sup>c,f,k</sup>	0.07 $\pm$ 0.01 <sup>d</sup>	23.43 $\pm$ 0.49 <sup>c,d</sup>	0.18 $\pm$ 0.00 <sup>f</sup>
Treatment control 1	11.39 $\pm$ 3.00 <sup>a,b,c,h</sup>	0.12 $\pm$ 0.01 <sup>a,b,c</sup>	30.00 $\pm$ 1.57 <sup>b</sup>	0.23 $\pm$ 0.014 <sup>b,c</sup>
Treatment control 2	12.31 $\pm$ 1.43 <sup>a,b</sup>	0.08 $\pm$ 0.02 <sup>c,d</sup>	22.62 $\pm$ 2.70 <sup>a,b,c,d</sup>	0.15 $\pm$ 0.03 <sup>b,d,t,h,k</sup>
Treatment control 3	7.50 $\pm$ 0.05 <sup>h,k</sup>	0.15 $\pm$ 0.02 <sup>b</sup>	19.39 $\pm$ 0.17 <sup>a</sup>	0.07 $\pm$ 0.00 <sup>a,l</sup>
Treatment 1	10.32 $\pm$ 0.92 <sup>a,b,c</sup>	0.11 $\pm$ 0.01 <sup>a,c</sup>	23.75 $\pm$ 1.53 <sup>c,d</sup>	0.14 $\pm$ 0.01 <sup>h,k</sup>
Treatment 2	19.43 $\pm$ 3.33 <sup>b</sup>	0.09 $\pm$ 0.01 <sup>a,b,c,d</sup>	18.5 $\pm$ 1.29 <sup>a</sup>	0.12 $\pm$ 0.01 <sup>d</sup>
Treatment 3	12.90 $\pm$ 2.48 <sup>a,b,c,h</sup>	0.12 $\pm$ 0.01 <sup>a</sup>	19.48 $\pm$ 0.12 <sup>a</sup>	0.05 $\pm$ 0.01 <sup>l</sup>

Values are mean  $\pm$  s.e.m., n=5, per group.

<sup>a,b,c</sup>Values in the same column with different superscripts are significantly different at  $P < 0.05$ .

## DISCUSSION

Alloxan induced diabetes mellitus is often characterized by decreased levels of insulin and high density lipoprotein, hyperglycemia, elevated triglycerides and total cholesterol (Hemalatha, 2008). The high percentage reduction in plasma glucose levels, produced by the extract in this study, supports the use of the leaves in the management of diabetes mellitus. The extract may exert its antihyperglycemic activity by stimulating insulin secretion from pancreatic  $\beta$  cells exerting insulin like activity, or by

converting pro-insulin to insulin, or alternatively, by inhibiting hepatic gluconeogenesis. The hypoglycemic effect of the extract may have been produced by the saponins (Ikewuchi et al., 2009), tannic acid and  $\beta$ -sitosterol (Table 3) present in the leaves. Saponins (Soetan, 2008), tannic acid (Liu et al., 2001, 2005; Muthusamy et al., 2008; Pereira et al., 2009) and  $\beta$ -sitosterol (Ivorra et al., 1988; Beta-sitosterol Monograph, 2001) are compounds with established hypoglycemic activity. The extract may exert its antihyperglycemic activity by enhancing glucose uptake (by tannic acid), stimulation

of insulin secretion from pancreatic  $\beta$  cells (by  $\beta$ -sitosterol) and insulin like activity, or by conversion of pro-insulin to insulin, or alternatively, by inhibition of hepatic gluconeogenesis.

A high plasma triglyceride level is both an independent and synergistic risk factor for cardiovascular diseases (Dobiášová, 2004; McBride, 2007; Martirosyan et al., 2007); and is often associated with hypertension (Lopes et al., 1997; Zicha et al., 1999), abnormal lipoprotein metabolism, obesity, insulin resistance and diabetes mellitus (McBride, 2007; Franz et al., 2002; Shen, 2007). The 300 mg/kg treatment significantly reduced plasma levels of triglycerides (Table 4). This effect may have been mediated by the flavonoid (Ikewuchi et al., 2009) and tannic acid (Table 3) contents of the leaves. Flavonoids (Middleton et al., 2000) and tannic acid (Park et al., 2002) are reported to decrease plasma levels of triglycerides.

High plasma levels of VLDL cholesterol is a risk factor for cardiovascular disease (Ademuyiwa et al., 2005; Lichtenstein et al., 2006) and often accompanies diabetes mellitus (Brunzell et al., 2008; Shen, 2007; Rang et al., 2005) and obesity (Krauss et al., 2006). In this study, we observed a significantly lower plasma VLDL cholesterol level in the treated animals. This cholesterol lowering effect of the extract may be due to its content of  $\beta$ -sitosterol and tannic acid (see Table 3) which are known to have cholesterol lowering and atheroprotective activity (Dillard and German, 2000; Yugarani et al., 1993; Piironen et al., 2000; Park et al., 2002; Bouic, 2003; Berger et al., 2004; Basu et al., 2007). Thus, anyone or a combination of some or all of the above mentioned components could have been responsible for the hypocholesterolemic effect of the extract, observed in this study.

The treatment dose dependently lowered (though not significantly) the atherogenic indices of the animals. Atherogenic indices are powerful indicators of the risk of heart disease: the higher the value, the higher the risk of developing cardiovascular disease

and vice versa (Dobiášová, 2004; Martirosyan et al., 2007; Brehm et al., 2004; Usoro et al., 2006). Low atherogenic indices are protective against coronary heart disease (Usoro et al., 2006).

These results indicate that the extract has a dose dependent positive effect on the integrity and function of the liver and kidney of the diabetic rats. The extract improved the lowered plasma calcium level produced by the diabetic condition. The significance of this cannot be overemphasized. Many neuromuscular and other cellular functions depend on the maintenance of the ionized calcium concentration in the extracellular fluid (Crook, 2006). Calcium fluxes are also important mediators of hormonal effects on target organs through several intracellular signaling pathways, such as the phosphoinositide and cyclic adenosine monophosphate systems (Crook, 2006; FAO, 2004). The extract may have achieved this by affecting parathyroid hormone secretion. This hormone increases the renal tubular reabsorption of calcium, promotes intestinal calcium absorption by stimulating the renal production of 1,25-dihydroxyvitamin D or calcitriol (1,25-(OH)<sub>2</sub>D), and, if necessary, resorbs bone (Crook, 2006; Brown and Hebert, 1997). Collectively, these results indicate that the extract dose dependently improved the liver and kidney functions.

Ascorbic acid functions as an important component of the cellular defense against oxygen toxicity and lipid peroxidation which is caused by the free radical mechanism. Reduced levels and the altered metabolic turnover of ascorbic acid have been reported in diabetic patients. A decrease in the plasma concentration of ascorbic acid has been observed in diabetic patients (Atalay and Laaksonen, 2002; Samuel et al., 2010). The uptake of ascorbic acid into the cell is mediated by processes which are re-

**Table 10:** Effect of an aqueous extract of the leaves of *Tridax procumbens* leaves on the haematological indices of normal and alloxan-induced diabetic rats

Parameter	Magnitude								
	Normal	Test control	Reference	Treatment control 1	Treatment control 2	Treatment control 3	Treatment 1	Treatment 2	Treatment 3
Haematocrit (%)	34.4±2.6 <sup>a,b,c</sup>	38.8±2.2 <sup>a,c</sup>	31.0±0.5 <sup>b</sup>	39.5±2.4 <sup>a,c</sup>	36.5±2.6 <sup>a,b,c</sup>	39.0±1.6 <sup>a,c</sup>	35.0±2.5 <sup>b,c</sup>	42.3±1.3 <sup>a</sup>	42.0±1.0 <sup>a</sup>
Haemoglobin concentration (g/dL)	12.0±0.5 <sup>a,b,c</sup>	12.3±0.5 <sup>a,c</sup>	11.4±0.1 <sup>c</sup>	13.0±0.5 <sup>a,b,t</sup>	12.2±0.6 <sup>a,b,c</sup>	12.3±0.4 <sup>a,c</sup>	11.6±0.7 <sup>c,t</sup>	13.9±0.3 <sup>b</sup>	13.4±0.3 <sup>a,b</sup>
Red cell count (x 10 <sup>9</sup> cells/L)	5.7±0.2 <sup>a,c</sup>	6.7±0.4 <sup>a,b,f</sup>	5.5±0.0 <sup>c,d</sup>	7.0±0.5 <sup>b,f</sup>	6.4±0.4 <sup>a,b,c,d,f</sup>	6.9±0.2 <sup>b,f</sup>	6.3±0.4 <sup>c,d,f</sup>	7.4±0.2 <sup>b</sup>	7.2±0.4 <sup>a,b</sup>
Total white cell count (x10 <sup>9</sup> cells/L)	9.7±1.1 <sup>a</sup>	11.9±1.3 <sup>b</sup>	10.2±1.0 <sup>a,b</sup>	18.7±3.1 <sup>b</sup>	17.3±3.6 <sup>a,b</sup>	13.7±1.3 <sup>a,b</sup>	12.0±1.4 <sup>a,b</sup>	11.6±3.9 <sup>a,b</sup>	10.6±0.3 <sup>a,b</sup>
Neutrophils (%)	5.3±1.0 <sup>a,c</sup>	3.7±0.4 <sup>c</sup>	5.5±1.4 <sup>c</sup>	5.0±1.9 <sup>b,c</sup>	6.4±1.5 <sup>a,b,c</sup>	11.3±1.3 <sup>a</sup>	5.3±1.0 <sup>a,c</sup>	10.3±0.2 <sup>b</sup>	4.5±0.2 <sup>c</sup>
Lymphocytes (%)	81.7±3.7 <sup>a,b,c</sup>	83.3±2.3 <sup>a</sup>	77.5±1.4 <sup>a,c</sup>	84.0±4.1 <sup>a,c</sup>	79.4±2.5 <sup>b,c</sup>	72.7±0.8 <sup>b</sup>	85.3±2.9 <sup>a,c</sup>	75.3±3.3 <sup>b,c</sup>	81.0±1.6 <sup>a,c</sup>
Monocytes (%)	12.8±2.7 <sup>a,b,c</sup>	12.8±2.0 <sup>a,b,c</sup>	15.6±1.4 <sup>a</sup>	11.0±2.5 <sup>a,b,c</sup>	14.9±1.5 <sup>a,c</sup>	16.6±0.7 <sup>a,c</sup>	9.5±1.8 <sup>b</sup>	14.5±3.3 <sup>a,b,c</sup>	14.5±1.5 <sup>a,b,c</sup>
Eosinophils (%)	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>
Basophils (%)	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>
Mean cell volume (fL)	58.7±3.2 <sup>a,b</sup>	57.5±1.5 <sup>a,b</sup>	56.5±0.5 <sup>a</sup>	57.5±1.9 <sup>a,b</sup>	57.0±1.0 <sup>a,b</sup>	59.9±1.6 <sup>b</sup>	55.5±1.1 <sup>a,b</sup>	57.5±1.3 <sup>a,b</sup>	57.8±1.2 <sup>a,b</sup>
Mean cell haemoglobin concentration (g/dL)	35.5±1.2 <sup>a,b,d</sup>	34.1±0.5 <sup>a,b,d</sup>	36.3±0.6 <sup>a</sup>	33.4±0.4 <sup>b</sup>	32.2±1.7 <sup>b,f</sup>	34.5±1.0 <sup>a,b,d</sup>	36.5±0.7 <sup>a,d</sup>	34.6±0.3 <sup>d,f</sup>	33.9±0.3 <sup>b,f</sup>
Mean cell haemoglobin (pg/cell)	20.8±0.7 <sup>a,b</sup>	19.8±0.3 <sup>a,b</sup>	20.5±0.2 <sup>a</sup>	19.1±0.5 <sup>a,b</sup>	19.7±0.1 <sup>b</sup>	19.4±0.1 <sup>b</sup>	20.1±0.6 <sup>a,b</sup>	19.9±0.4 <sup>a,b</sup>	19.5±0.4 <sup>b</sup>
Platelet count (x10 <sup>3</sup> cells/mm <sup>3</sup> )	447.8±33.3 <sup>a,c</sup>	340.8±54.1 <sup>c,d</sup>	343.0±8.9 <sup>d</sup>	494.0±29.5 <sup>b,c</sup>	425.5±54.8 <sup>a,c,d</sup>	581.9±24.4 <sup>b</sup>	396.0±26.5 <sup>a,d</sup>	503.7±66.3 <sup>a,b,c,d</sup>	431.5±4.9 <sup>a,c</sup>

Values are mean ± s.e.m., n=5, per group.

<sup>a,b,c</sup>Values in the same row with different superscripts are significantly different at  $P < 0.05$ .

lated to glucose transport and it has been shown that the high extracellular glucose concentration in diabetes may further impair the cellular uptake of ascorbic acid and accentuate the problems which are associated with its deficiency (Samuel et al., 2010). Studies show that ascorbic acid protects the lens and other tissues of the eye from light damage (Varma, 1991; Taylor, 1993). So, these increases caused by the extract, portends a consolidation of antioxidant status of the tissues, hence protection of these tissues from free radical damage. This high ocular content of ascorbic acid may have been produced by the high content of ascorbic acid in the leaves (Ikewuchi and Ikewuchi, 2009a).

Numerous reports indicate variations in the levels of antioxidants in the diabetic patients (Samuel et al., 2010; Hartnett et al., 2000). Therefore, though the lowered enzyme activities produced by the extract may portend compromised antioxidant protection; the antioxidant vitamins in the test rats clearly indicate that the extract protects against oxidative stress in ocular tissues and probably may have cushioned against the compromised antioxidant enzymes.

The extract had a dose dependent positive effect on the haemopoietic system of the test rats. It increased (though not significantly) the red cell mass, haematocrit and monocyte counts, and platelet number; significantly increased haemoglobin concentration and neutrophil count, while decreasing lymphocyte count. That the extract improved the haemoglobin concentration and haematocrit highlights the potential of the plant in the management of anaemia. This property may be attributable to the iron contained by the leaves (Ikewuchi and Ikewuchi, 2009b).

### CONCLUSIONS

This study showed that the extract was hypoglycemic, positively affected the haemopoietic system and integrity and function (dose dependently) of the liver and kidney of the diabetic rats; improved the lipid profile and had no deleterious effect on red cell

morphology. The profiles of malondialdehyde and antioxidant vitamins in the test rats clearly indicate that the extract protects against oxidative stress in ocular tissues. This study also revealed the presence of pharmacologically active compounds in the leaf extract. All of these, highlight the cardioprotective potential of the leaves of *Tridax procumbens*, and support its use in traditional health care practices for the management of diabetes mellitus.

### REFERENCES

- Acharya S, Srivastava RC. Antifungal property of *Tridax procumbens* L. against three phytopathogenic fungi. Arch Pharmaceut Sci Res 2010;2:258–63.
- Acuff RV, Cai DJ, Dong ZP, Bell D. The lipid lowering effect of plant sterol ester capsules in hypercholesterolemic subjects. Lipids Health Dis 2007;6:1.
- Ademuyiwa O, Ugbaja RN, Idumebor F, Adebawo O. Plasma lipid profiles and risk of cardiovascular disease in occupational lead exposure in Abeokuta, Nigeria. Lipids Health Dis 2005;4:19.
- Agrawal S, Khadase S, Talele G. Bioactive immunomodulatory fraction from *Tridax procumbens*. Asian J Biol Sci 2010;3(3):20-7.
- Ahirwar V, Singh K, Rani S, Srivastava A, Gul T. Effect of *Tridax procumbens* on protein contents of various organs in female albino rats. Int J Pharmaceut Sci Res 2010;1(9):78-81.
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27:S5-S10.
- Amos AF, McCarty DJ, Zimmet P. Diagnosis and classification of diabetes mellitus. Diabet Med 1997;14:S1-S8.

AOAC International. Cholesterol in foods. Direct saponification-gas chromatographic method. AOAC Official Method 994.10. AOAC International, Gaithersberg (USA), 2000.

AOAC International. Oil in seeds. Supercritical fluid extraction (SFE) method. AOAC Official Method 999.02. AOAC International, Gaithersberg (USA), 2002.

AOAC International. Official methods of analysis of the AOAC (Horwitz W, ed.), 18<sup>th</sup> ed. AOAC International, Washington DC, USA, 2006.

Atalay M, Laaksonen DE. Diabetes, oxidative stress and physical exercise. *J Sports Sci Med* 2002;1:1-14.

Baginsky ES, Marie SS, Clark WL, Zak B. Direct micro-determination of calcium. *Clin Chim Acta* 1973;46:49-54.

Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes. *Diabetes Care* 1989;12:553-64.

Basu SK, Thomas JE, Acharya SN. Prospects for growth in global nutraceutical and functional food markets: A Canadian perspective. *Aust J Basic Applied Sci* 2007;1:637-49.

Beers RF, Sizer IW. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. *Biol Chem* 1952;195:130-40.

Berger A, Jones PJH, Abumweis SS. Plant sterols: factors affecting their efficacy and safety as functional food ingredients. *Lipids Health Dis* 2004;3:5.

Beta-sitosterol monograph. Plant sterols and sterolins. *Altern Med Rev* 2001;6: 203-6.

Bouic PJD. The role of plant sterols in dietary control of high plasma cholesterol levels. *South Afr J Clin Nutr* 2003;16(2): 40-1.

Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M. Relationship between serum lipoprotein ratios and insulin resistance in obesity. *Clin Chem* 2004;50:2316–22.

Brown EM, Hebert SC. Calcium-receptor-regulated parathyroid and renal function. *Bone* 1997;20:303–9.

Brunzell JD, Davidson M, Furberg CD, Goldberg RD, Howard BV, Stein JH et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. *J Am Coll Cardiol* 2008;51:1512-24.

Burcelin R, Eddouks M, Maury J, Kande J, Assan R, Girard J. Excessive glucose production, rather than insulin resistance, account for hyperglycemia in recent onset streptozocin-diabetic rats. *Diabetologia* 1995;385:283-90.

Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.

Cheesbrough M. District laboratory practice in tropical countries, Part 1. Cambridge, UK: Cambridge University Press, 2006.

Crook MA. Clinical chemistry and metabolic medicine 7<sup>th</sup> ed. London: Holder Arnold, 2006.

Dillard CJ, German JB. Phytochemicals: nutraceuticals and human health. *J Sci Food Agric* 2000;80:1744–56.

Dobiášová M. Atherogenic index of plasma (log(triglyceride/HDL-Cholesterol)): theoretical and practical implications. *Clin Chem* 2004;50:1113-5.



- Edeoga HO, Okwu, DE, Mbaebie BO. Phytochemical constituents of some Nigerian medicinal plants. *Afr J Biotech* 2005;4: 685-8.
- FAO. Vitamin and mineral requirements in human nutrition, 2<sup>nd</sup> ed. A report of a Joint FAO/WHO Expert Consultation, Bangkok, Thailand, 2004.  
<http://whqlibdoc.who.int/publications/2004/9241546123.pdf>
- Fosberg FR, Sacht M-H. Flora of micronesia, 4: *Caprifoliaceae-Compositae*. Smithsonian contributions to botany number 46 (71 p). Washington, DC: Smithsonian Institution Press, 1980.
- Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. *Diabetes Care* 2002;25:148-98.
- Friedewald WT, Levy RI, Friedrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499-502.
- Gutteridge JMC, Wilkins C. Copper-dependent hydroxyl radical damage to ascorbic acid. Formation of a thiobarbituric acid reactive products. *FEBS Letters* 1982; 137:327-40.
- Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong D. Serum markers of oxidative stress and severity of diabetic retinopathy. *Diabetes Care* 2000;23:234-40.
- Hemalatha R. Anti-hepatotoxic and antioxidant defense potential of *Tridax procumbens*. *Intern J Green Pharm* 2008;2: 164-9.
- Hunter FE, Gebicki JM, Hoffstein PE, Weinstein J, Scott A. Swelling and lysis of rat liver mitochondria induced by ferrous ions. *J Biol Chem* 1963;238:828-35.
- Ikewuchi CC, Ikewuchi JC. Comparative study on the vitamin composition of some common Nigerian medicinal plants. *Pac J Sci Tech* 2009a;10:367-71.
- Ikewuchi JC, Ikewuchi CC. Comparative study of the mineral element composition of some common Nigerian medicinal plants. *Pac J Sci Tech* 2009b;10:362-6.
- Ikewuchi JC, Ikewuchi CC. Alteration of plasma lipid profile and atherogenic indices of cholesterol loaded rats by *Tridax procumbens* Linn: Implications for the management of obesity and cardiovascular diseases. *Biokemistri* 2009c;21(2):95-9.
- Ikewuchi JC, Ikewuchi CC. Alteration of plasma lipid profiles and atherogenic indices by *Stachytarpheta jamaicensis* L. (Vahl). *Biokemistri* 2009d;21(2):71-7.
- Ikewuchi JC, Ikewuchi CC, Igboh MN. Chemical profile of *Tridax procumbens* Linn. *Pak J Nutr* 2009;8:548-50.
- Ikewuchi JC, Ikewuchi CC. Hypocholesterolaemic effect of aqueous extract of *Acalypha wilkesiana* 'Godseffiana' Muell Arg on rats fed egg yolk supplemented diet: Implications for cardiovascular risk management. *Res J Sci Tech* 2010; 2(4): 78-81.
- Ikewuchi JC, Ikewuchi CC, Onwuka FC. Effect of aqueous extract of *Tridax procumbens* Linn on plasma electrolytes of salt-loaded rats. *Pak J Nutr* 2010;9:103-5.
- Ikewuchi JC, Ikewuchi CC. Iodometric determination of the ascorbic acid (vitamin C) content of some fruits consumed in a university community in Nigeria. *Global J Pure Appl Sci* 2011;17:47-9.

- Ikewuchi JC, Onyeike EN, Uwakwe AA, Ikewuchi CC. The weight reducing and hypocholesterolemic effect of aqueous extract of the leaves of *Tridax procumbens* Linn on sub-chronic salt-loaded rats. Intern J Biol Chem Sci 2011a;5:680-7.
- Ikewuchi JC, Onyeike EN, Uwakwe AA, Ikewuchi CC. Effect of aqueous extract of the leaves of *Tridax procumbens* Linn on Blood pressure components and pulse rates of sub chronic salt-loaded rats. Pac J Sci Tech 2011b;12:381-9.
- Ivorra MD, D'Ocon MP, Paya M, Villar A. Antihyperglycemic and insulin-releasing effects of  $\beta$ -sitosterol 3- $\beta$ -D-Glucoside and its aglycone,  $\beta$ -sitosterol. Arch Intern Pharmacodyn Therap 1988;296:224-31.
- Jahangir M. Chemical and biological studies on some members of Asteraceae family and *Pseudocalymma elegans*, a native of Brazil. PhD Thesis Submitted to the International Center for Chemical Sciences H.E.J, Research Institute of Chemistry, University of Karachi, Karachi-75270, Pakistan, 2001.
- Jyoti M, Vihas TV, Ravikumar A, Sarita G. Glucose lowering effect of aqueous extract of *Enicostemma littorale* Blume in diabetes: a possible mechanism of action. J Ethnopharmacol 2002;81:317-20.
- Kamboj VP. Herbal medicine. Curr Sci 2000;78:35-51.
- Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, Williams PT. Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. Am J Clin Nutr 2006;83:1025–31.
- Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franklin B et al. Diet and lifestyle recommendations revision 2006. A scientific statement from the American Heart Association Nutrition Committee. Circulation 2006;114:82-96.
- Liu F, Kim J, Li Y, Liu X, Li J, Chen X. An extract of *Lagerstroemia speciosa* L. has insulin-like glucose uptake-stimulatory and adipocyte differentiation-inhibitory activities in 3T3-L1 cells. J Nutr 2001;131:2242-7.
- Liu X, Kim J-K, Li Y, Li J, Liu F, Chen X. Tannic acid stimulates glucose transport and inhibits adipocyte differentiation in 3T3-L1 cells. J Nutr 2005;135:165–71.
- Lopes FH, Bernardes Silva H, Soares JA, Filho B, Consolim-Colombo FM, Giorgi DMA et al. Lipid metabolism alterations in normotensive subjects with positive family history of hypertension. Hypertension 1997;30:629-31.
- Luthar Z. Polyphenol classification and tannin content of buckwheat seeds (*Fagopyrum esculentum* Moench). Fagopyrum 1992;12:36–42.
- Martirosyan DM, Miroshnichenko LA, Kulokawa SN, Pogojeva AV, Zoloedov VI. Amaranth oil application for heart disease and hypertension. Lipids Health Dis 2007;6:1.
- McBride PE. Triglycerides and risk for coronary heart disease. JAMA 2007;298:336-8.
- Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease and cancer. Pharmacol Rev 2000;52:673-751.
- Misra HP, Fridovich I. The role of superoxide anion in the auto-oxidation of epinephrine and a single assay for superoxide dismutase. J Biol Chem 1989;247:3170-5.
- Muthusamy VS, Anand S, Sangeetha KN, Sujatha S, Lakshmi BABS. Tannins present in *Cichorium intybus* enhance glucose uptake and inhibit adipogenesis in 3T3-L1 adipocytes through PTP1B inhibition. Chem Biol Interact 2008;174:69-78.

- Park S-Y, Bok S-H, Jeon S-M, Park YB, Lee S-J, Jeong TS et al. Effect of rutin and tannic acid supplements on cholesterol metabolism in rats. *Nutr Res* 2002;22:283-95.
- Pereira DM, Valentão P, Pereira JA, Andrade PB. Phenolics: From chemistry to biology. *Molecules* 2009;14:2202-11.
- Piironen V, Lindsay DG, Miettinen TA, Toivo J, Lampi A-M. Plant sterols: biosynthesis, biological function and their importance to human nutrition. *J Sci Food Agric* 2000;80:939-66.
- Prabhu VV, Nalini G, Chidambaranathan N, Kisan NS. Evaluation of anti inflammatory and analgesic activity of *Tridax procumbens* Linn against formalin, acetic acid and CFA induced pain models. *Int J Pharm Pharm Sci* 2011;3:126-30.
- Prajapati K, Singh D, Mishra SD, Dubey P, Sangameswaran B. Pharmacognostical and preliminary phytochemical studies of leaves of *Tridax procumbens* L. *Ethnobot Leaflets* 2008;12:1283-9.
- Radwan MA. Enhancement of absorption of insulin-loaded polyisobutylcyanoacrylate nanospheres by sodium cholate after oral and subcutaneous administration in diabetic rats. *Drug Dev Ind Pharmacy* 2001;27:383-91.
- Rang HP, Dale MM, Ritter JM, Moore PK. *Pharmacology*, 5<sup>th</sup> ed. Elsevier, India, 2005.
- Ravikumar V, Shivashangari KS, Devaki T. Hepatoprotective activity of *Tridax procumbens* against d-galactosamine/lipopolysaccharide-induced hepatitis in rats. *J Ethnopharmacol* 2005;101(1-3):55-60.
- Rolfe M, Tanga CM, Walker RW, Bassey E, George M. Diabetes mellitus in the Gambia, West Africa. *Diabet Med* 1992;9:484-8.
- Salahdeen HM, Yemitan OK, Alada ARA. Effect of aqueous leaf extract of *Tridax procumbens* on blood pressure and heart rate in rats. *Afr J Biomed Res* 2004;7:27-9.
- Samuel VT, Jayaprakash Murthy DS, Dattatreya K, Babu PS, Johny SS. Impaired antioxidant defence mechanism in diabetic retinopathy. *J Clin Diag Res (serial online)* 2010;4(6):3430-6.
- Saxena VK, Albert S.  $\beta$ -Sitosterol-3-O- $\beta$ -D-xylopyranoside from the flowers of *Tridax procumbens* Linn. *J Chem Sci* 2005;117:263-6.
- Shen GX. Lipid disorders in diabetes mellitus and current management. *Curr Pharmaceut Anal* 2007;3:17-24.
- Soetan KO. Pharmacological and other beneficial effects of antinutritional factors in plants - A review. *Afr J Biotechnol* 2008;7(25):4713-21.
- Taylor A. Relationship between nutrition and oxidation. *J Am Coll Nutr* 1993;12:138-46.
- Tram NTC, Mitova M, Bankova V, Handjieva N, Popov SS. GC-MS of *Crinum latifolium* L. alkaloids. *Z Naturforsch* 2002;57c:239-42.
- United States Department of Agriculture, Agricultural Research Service, National Genetic Resources Program. Germplasm Resources Information Network - (GRIN) (Online Database). National Germplasm Resources Laboratory, Beltsville, Maryland. <http://www.ars-grin.gov/cgi-bin/npgs/html/taxon.pl?40146> (14 March 2011).
- Usoro CAO, Adikwuru CC, Usoro IN, Nsonwu AC. Lipid profile of postmenopausal women in Calabar, Nigeria. *Pak J Nutr* 2006;5:79-82.

Varma SD. Scientific basis of medical therapy of cataracts by antioxidants. *Am J Clin Nutr* 1991;53:335S-45S.

Wardlaw GM. *Perspectives in nutrition*. 4<sup>th</sup> ed. London: McGraw-Hill, 1999.

World Health Organization. *Diabetes action now: an initiative of the World Health Organization and International Diabetes Federation*. Geneva: WHO, 2004 (WHO publication, 4).

Yugarani T, Tan BK, Das NP. The effects of tannic acid on serum and liver lipids of RAIF and RICO rats fed on high fat diet. *Comp Biochem Physiol Comp Physiol* 1993;104:339-43.

Zicha J, Kunes J, Devynck MA. Abnormalities of membrane function and lipid metabolism in hypertension: a review. *Am J Hypertens* 1999;12:315-31.